GLP-1 receptor agonist
Exenatide
Exenatide's mean terminal half-life is 2.4 hours on the Byetta label, the same as the app's figure.1
Exenatide after one dose: 50% at ~2.4 h, 25% at 4.8 h, 12.5% at 7.2 h.
Drawn from the half-life in the app's model, ~2.4 h. The model's figures
- Compound
- Exenatide
- Symbol
- EXN
- Family
- GLP-1 and incretin
- Parts
- 14
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Exenatide is a GLP-1 receptor agonist that the Byetta label describes as a synthetic peptide "originally identified in the lizard Heloderma suspectum".1 The US labels describe two products: Byetta, started at 5 mcg twice daily, and Bydureon BCise, an extended-release suspension given at 2 mg once every seven days.1,2
Both labels give 2005 as the initial US approval year.1,2 The Byetta label lists one use, in adults with type 2 diabetes mellitus, as "an adjunct to diet and exercise to improve glycemic control".1 The Bydureon BCise label lists the same use in adults "and pediatric patients aged 10 years and older with type 2 diabetes mellitus".2
The app grades the evidence for exenatide as strong. The trials described below were funded by Amylin Pharmaceuticals (EXSCEL), the Michael J Fox Foundation for Parkinson's Research (Athauda and colleagues) and the National Institute for Health and Care Research with Cure Parkinson's (the UK phase 3 Parkinson's trial).3,4,5
How it works
Sources in this part
The Byetta label states that "Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion" and that Byetta "enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying".1 The label adds that "The amino acid sequence of exenatide partially overlaps that of human GLP-1", and that exenatide "has been shown to bind and activate the human GLP-1 receptor in vitro".1 On food intake, the label says "In both animals and humans, administration of exenatide has been shown to reduce food intake".1 The Bydureon BCise label describes its product as "a sterile suspension of exenatide extended-release microspheres in an oil-based vehicle", and says exenatide is a "39-amino acid synthetic peptide amide".2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2.4 h
- Bioavailability
- 65%
- Typical dose
- 5–20 mcg/day
- Route
- SubQ
- Time to peak
- ~2 h
The second column of the table holds the app's own figures, shown beside what the sources report. The app's kinetics are for the immediate-release Byetta form, modelled as one compartment.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~2.4 h | Mean terminal half-life of 2.4 hours on the Byetta label, "independent of the dose"; 0.99 to 1.25 hours in 24 healthy Chinese volunteers given 5 or 10 mcg; mean 1.5 hours in 8 healthy people with normal renal function in a single-dose study1,6,7 |
| Bioavailability | 65% | The Byetta and Bydureon BCise label texts read contain no bioavailability figure1,2 |
| Time to peak | ~2 h | Median peak plasma concentration at 2.1 hours after subcutaneous dosing in patients with type 2 diabetes on the Byetta label; median tmax of 1 hour in the healthy Chinese volunteers; for the extended-release form, a plasma peak "at around Week 6 to Week 7"1,6,2 |
| Volume of distribution and clearance | Not listed | Mean apparent volume of distribution of 28.3 L and apparent clearance of 9.1 L/hour on the Byetta label; Vz/F of 19.2 to 22.3 L and CL/F of 11.4 to 13.5 L/h in the Chinese volunteers1,6 |
| Kidney function | Not listed | Mean half-life of 1.5, 2.1, 3.2 and 6.0 hours in people with normal function, mild or moderate renal impairment and end-stage renal disease on haemodialysis in a single-dose study of 31 people; on the Bydureon BCise label, 28% and 69% higher exposure in mild (N=96) and moderate (N=24) impairment than in normal function (N=70)7,2 |
| Extended-release form | Not listed | Gradual rise in plasma concentration "up to approximately Week 10", then mean concentrations of approximately 208 pg/mL; about 10 weeks after stopping, concentrations generally fall below 20 pg/mL2 |
The study by Zhao and colleagues (Peking University First Hospital, International Journal of Clinical Pharmacology and Therapeutics, 2008) was a 24-person pharmacokinetic study whose PubMed record gives no funding statement and lists the publication type "Research Support, Non-U.S. Gov't".6 Linnebjerg and colleagues (British Journal of Clinical Pharmacology, 2007) state "This work was sponsored by Eli Lilly and Co. and Amylin Pharmaceuticals, Inc.", and the first author's affiliation is Eli Lilly.7
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: twice daily (Byetta label)1.
An illustration from a pharmacokinetic model using a half-life of 2.4 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Holman and colleagues, EXSCEL, New England Journal of Medicine 20173 | Pragmatic, randomised, double-blind, placebo-controlled, event-driven; registry status completed; funded by Amylin Pharmaceuticals3,8 | 14,752 adults with type 2 diabetes, 73.1% with previous cardiovascular disease3 | Extended-release exenatide 2 mg or matching placebo once weekly; median follow-up 3.2 years3 | Primary composite 839 of 7356 (11.4%) against 905 of 7396 (12.2%), hazard ratio 0.91 (95% CI 0.83 to 1.00): noninferior for safety, not superior for efficacy (P = 0.06); all-cause death hazard ratio 0.86 (0.77 to 0.97), not considered significant under the hierarchical testing plan3 |
| Athauda and colleagues, Lancet 20174 | Single-centre, randomised, double-blind, placebo-controlled; funded by the Michael J Fox Foundation4 | 62 people with moderate Parkinson's disease on dopaminergic treatment: 32 exenatide, 30 placebo4 | Exenatide 2 mg or placebo once weekly for 48 weeks, then a 12-week washout4 | Off-medication MDS-UPDRS part 3 at 60 weeks: adjusted mean difference -3.5 points (-6.7 to -0.3; p=0.0318); on-medication scores did not differ significantly; 6 serious adverse events with exenatide and 2 with placebo, none judged related to the study interventions4 |
| Vijiaratnam and colleagues, Lancet 2025 (Expression of Concern, Lancet 2026)5,9 | Phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled at six UK hospitals; funded by the National Institute for Health and Care Research and Cure Parkinson's5 | 194 people aged 25 to 80 with Parkinson's disease: 97 exenatide, 97 placebo5 | Extended-release exenatide 2 mg once weekly or placebo for 96 weeks5 | Off-medication MDS-UPDRS III worsened by 5.7 points (SD 11.2) with exenatide and 4.5 (SD 11.4) with placebo (adjusted coefficient 0.92, 95% CI -1.56 to 3.39; p=0.47); the authors "found no evidence to support exenatide as a disease-modifying treatment"5 |
| Byetta label, 24-week monotherapy trial1 | Randomised, double-blind, placebo-controlled; label summary1 | Patients with entry HbA1c of 6.5% to 10%: 77 on 5 mcg, 78 on 10 mcg, 77 on placebo1 | Byetta 5 mcg or 10 mcg twice daily, or placebo, for 24 weeks, all Byetta arms starting at 5 mcg twice daily for 4 weeks1 | Statistically significant reductions in HbA1c from baseline against placebo at Week 24 for both doses; the label text gives the figures in a table; two of the 155 Byetta-treated patients withdrew due to adverse reactions (headache and nausea) and no placebo-treated patients did1 |
Deeper analysis: EXSCEL
Holman and colleagues reported EXSCEL for the EXSCEL Study Group in the New England Journal of Medicine in 2017, and the trial was "conducted jointly by the Duke Clinical Research Institute and the University of Oxford Diabetes Trials Unit in collaboration with the sponsor".3 The authors call it a "pragmatic, randomized, double-blind, placebo-controlled, event-driven trial at 687 sites in 35 countries".3 Adults with type 2 diabetes were eligible if their glycated hemoglobin was 6.5 to 10.0%, with about 70% planned to have had previous cardiovascular events.3 Exclusions included end-stage kidney disease or an eGFR below 30, a personal or family history of medullary thyroid carcinoma, and previous treatment with a GLP-1 receptor agonist.3 At baseline the median duration of diabetes was 12.0 years, the median glycated hemoglobin was 8.0%, and 2389 patients (16.2%) had a history of heart failure.3 The primary outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke.3 It occurred in 839 of 7356 patients (11.4%) on exenatide and 905 of 7396 (12.2%) on placebo, a hazard ratio of 0.91 (95% CI 0.83 to 1.00), which met the noninferiority test for safety (P less than 0.001) but not the superiority test (P = 0.06).3 All-cause death was 6.9% against 7.9% (hazard ratio 0.86; 95% CI 0.77 to 0.97), but the authors state this "was not considered to be statistically significant on the basis of the hierarchical testing plan".3 Rates of the first fatal or nonfatal myocardial infarction, fatal or nonfatal stroke and other secondary outcomes "did not differ significantly between the two groups".3 At 6 months the mean glycated hemoglobin was 0.7 percentage points lower on exenatide; over the whole trial the least-squares mean difference was -0.53% (95% CI -0.57 to -0.50).3 Heart rate was higher on exenatide by 2.51 beats per minute.3 On safety, "No clinically relevant between-group differences were seen in the incidence of serious adverse events or events of clinical interest".3 Any serious adverse event occurred in 1234 (16.8%) on exenatide and 1222 (16.6%) on placebo, serious events related to the trial regimen in 56 (0.8%) against 38 (0.5%), and serious events leading to permanent discontinuation in 108 (1.5%) against 104 (1.4%).3 Confirmed acute pancreatitis occurred in 26 and 22 patients, pancreatic cancer in 15 and 16, and medullary thyroid carcinoma in 2 and 1; "More patients in the exenatide group than in the placebo group had thyroid papillary carcinomas (10 vs. 4)".3 The authors note that all three patients with medullary thyroid carcinoma "had elevated calcitonin levels at baseline".3 In all, 14,187 patients (96.2%) completed the trial, and the mean share of expected time on the trial regimen "was 76.0% and 75.0%, respectively".3 The authors write: "A major limitation of our trial was the rate of premature discontinuation of the trial regimen, which was driven primarily by patient decision".3 On why efficacy was not shown, they suggest that "The disproportionate use in the placebo group of diabetes therapies known to reduce cardiovascular risk, such as SGLT-2 inhibitors, and GLP-1 receptor agonists, may have preferentially resulted in lower event rates in the placebo group", and open-label SGLT-2 inhibitor use was 6.5% against 9.4%.3 The article states "Supported by Amylin Pharmaceuticals, a wholly owned subsidiary of AstraZeneca", and the registry names AstraZeneca as lead sponsor.3,8 The steering committee was "composed of nine investigators and two employees of the sponsor", while "The statistical analyses were performed by the Duke Clinical Research Institute, independent of the sponsor".3 Four listed authors (Choi, Gustavson, Iqbal and Öhman) give their affiliation as "AstraZeneca Research and Development, Gaithersburg, MD"; the authors' disclosure forms are held at the journal site and were not in the text read.3
Deeper analysis: the Parkinson's disease trials
Athauda and colleagues (University College London group, Lancet, 2017) enrolled 62 people, 32 to exenatide and 30 to placebo, and the primary analysis included 31 and 29.4 The primary outcome was the off-medication MDS-UPDRS part 3 score at 60 weeks, after 48 weeks of weekly exenatide 2 mg and a 12-week washout.4 At 60 weeks scores had improved by 1.0 points on exenatide and worsened by 2.1 points on placebo, an adjusted mean difference of -3.5 points (-6.7 to -0.3; p=0.0318).4 The authors report that "no significant differences were noted between the exenatide and placebo groups in scores on parts 1–4 of the MDS-UPDRS (in the on-medication state), or in assessments of cognition, mood, dyskinesia, non-motor symptoms, or quality of life".4 Mean weight fell by 2.6 kg on exenatide and 0.6 kg on placebo at 48 weeks; injection site reactions and gastrointestinal symptoms were common adverse events in both groups; one exenatide-group patient stopped the drug for asymptomatic hyperamylasaemia at 12 weeks, and two placebo-group patients stopped injections, one after 9 weeks because of worsening anxiety and one after 36 weeks because of dyskinesia.4 One placebo-group patient developed pancreatic cancer shortly after the end of trial monitoring.4 The authors' limitations include that "the small size of our study meant that, despite randomisation with a block design according to Hoehn and Yahr status, the exenatide group had higher MDS-UPDRS part 3 scores and lower LED at baseline than the placebo group".4 They also write that "the differences we noted in off-medication scores were not supported by significant differences in clinical secondary outcomes".4 Their interpretation is that "Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain".4 Of the funder, they write that it "had roles in study design and data interpretation, but no role in data collection or analysis, or writing of the Article".4 The acknowledgements add that the work "was funded in part by the Department of Health National Institute for Health Research Biomedical Research Centres funding scheme" and that the analysis of exenatide concentrations "was partly supported by the Intramural Research Program of the US National Institutes of Health".4 One author (NHG) is "a named inventor on a National Institutes of Health patent describing the use of GLP-1 receptor agonists in neurodegenerative disorders", with the rights held by the US Government.4
Vijiaratnam and colleagues (University College London and five other UK centres, Lancet, 2025) randomised 194 people with Parkinson's disease, 97 to extended-release exenatide 2 mg once weekly and 97 to placebo for 96 weeks.5 Analyses covered 92 on exenatide and 96 on placebo with at least one follow-up visit.5 The primary outcome was the off-medication MDS-UPDRS part III score at 96 weeks.5 Scores worsened by 5.7 points on exenatide and 4.5 on placebo (adjusted coefficient 0.92; 95% CI -1.56 to 3.39; p=0.47), and nine (9%) on exenatide and 11 (11%) on placebo had at least one serious adverse event.5 The authors write "We found no evidence to support exenatide as a disease-modifying treatment for people with Parkinson's disease".5 The funders were the National Institute for Health and Care Research and Cure Parkinson's, and the declarations of interests record that the last author has received honoraria for talks sponsored by Novo Nordisk, among other companies.5 The PubMed record holds a summary, affiliations and declarations only, so the authors' limitations section was not read.5 The Lancet later published an expression of concern about this trial report, and the PubMed record for that notice holds no text beyond its title and publication type.9
Doses reported in studies and on labels
The app's typical dose is 5 to 20 mcg per day.1
| Source | Product and route | Dose reported | Context |
|---|---|---|---|
| Byetta label1 | Subcutaneous | 5 mcg twice daily as the starting dose, then 10 mcg twice daily "after 1 month of therapy"; 20 mcg/day is the label's maximum dose figure | Adults with type 2 diabetes mellitus; label also gives 5 mcg and 10 mcg per-dose pens1 |
| Bydureon BCise label2 | Extended-release suspension, subcutaneous | 2 mg once every seven days | Adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus2 |
| EXSCEL (Holman, 2017)3 | Extended-release, subcutaneous | 2 mg once weekly against matching placebo; median follow-up 3.2 years | 14,752 adults with type 2 diabetes3 |
| Athauda, 20174 | Subcutaneous | 2 mg once weekly or placebo for 48 weeks, then 12-week washout | 62 people with moderate Parkinson's disease4 |
| Vijiaratnam, 20255 | Extended-release, subcutaneous pen | 2 mg once per week or placebo over 96 weeks | 194 people with Parkinson's disease5 |
The Byetta label's starting dose of 5 mcg twice daily is 10 mcg per day, against the app's lower figure of 5 mcg per day.1
Side effects reported
For Byetta, the label lists the most common reactions (5% or more and more frequent than placebo) as nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation and asthenia, and adds "Nausea usually decreases over time".1 The label says nausea "occurred in a dose-dependent fashion"; the most common reasons for withdrawal were nausea (3% of patients) and vomiting (1%) in the metformin and/or sulfonylurea add-on trials, nausea (9%) and vomiting (5%) in the thiazolidinedione add-on trial, and nausea (5.1%) and vomiting (2.9%) in the insulin glargine add-on trial.1 Warnings on the Byetta label include "Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including BYETTA".1 Patients receiving Byetta with an insulin secretagogue or insulin "may have an increased risk of hypoglycemia including severe hypoglycemia".1 The label reports postmarketing "serious hypersensitivity reactions (e.g., anaphylaxis and angioedema)" and, from postmarketing use, serious bleeding "which may be fatal" from drug-induced immune-mediated thrombocytopenia.1 In patients with end-stage renal disease on dialysis, "single doses of BYETTA 5 mcg were not well tolerated due to gastrointestinal adverse reactions".1
The Bydureon BCise label carries a boxed warning on thyroid C-cell tumors: extended-release exenatide caused them "at clinically relevant exposures in rats", and "the human relevance" of the rodent findings has not been determined.2 The label states the product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia syndrome type 2.2 In pooled data from the controlled and extension phases of its two 28-week comparator-controlled adult trials (526 patients on 2 mg, mean exposure 35 weeks), reactions in 5% or more were injection site nodule and nausea, and injection site reactions of any kind were observed in 23.9% of patients; 3.9% discontinued because of adverse reactions, most often diarrhea (0.7%), nausea (0.7%), vomiting (0.5%) and injection-site nodule (0.5%).2 Less common reactions (above 2% and below 5%) included "headache (4.4%), diarrhea (4.0%), vomiting (3.4%)".2
In the healthy Chinese volunteers, adverse events were "gastrointestinal in nature and mild in severity" and more frequent at 10 mcg (42%) than at 5 mcg (8%).6 In the renal-impairment study, exenatide "was generally well tolerated in the mild and moderate RI groups, but not in subjects with ESRD due to nausea and vomiting".7
Bloodwork and markers
Sources in this part
The app lists HbA1c and fasting glucose as the markers to monitor. In EXSCEL, the least-squares mean HbA1c difference over the trial was -0.53% against placebo, and calcitonin was measured at a central laboratory at baseline and annually.3 In a single-dose crossover study of patients with type 2 diabetes and fasting hyperglycemia, the label says "Plasma glucose concentrations were significantly reduced with BYETTA compared with placebo".1 The Byetta label says renal function is to be monitored in patients reporting reactions that could lead to volume depletion, citing postmarketing acute kidney injury.1
Regulatory and anti-doping status
The Byetta label (on DailyMed) and the Bydureon BCise label (on the FDA's accessdata site) both give 2005 as the initial US approval.1,2 Neither a European Medicines Agency nor an Australian TGA document for exenatide was retrieved, so no statement is made about those regulators. The 2026 WADA Prohibited List text read contains no occurrence of "exenatide" and none of "GLP".10 The list has a section S2 for peptide hormones, growth factors, related substances and mimetics, and this search does not establish whether any of its categories applies to exenatide.10
Storage and handling
Sources in this part
What is not known
No bioavailability figure for exenatide appeared in the label texts read, so the app's 65% appears here without a figure from a label beside it.1,2 The reason for the Lancet's expression of concern about the UK phase 3 Parkinson's trial is not in the PubMed record read.9 Athauda and colleagues write that it is uncertain whether exenatide "affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects", and the larger later trial reported no benefit on its primary outcome.4,5 The app's note that exenatide is largely superseded by once-weekly semaglutide and tirzepatide is not tested by any source read.
Frequently asked questions
What is the half-life of exenatide?
How long does exenatide take to reach its peak level?
The Byetta label gives a median time to peak plasma concentration of 2.1 hours after subcutaneous dosing in patients with type 2 diabetes, close to the app's figure of about 2 hours.1 The Chinese volunteer study reported a median tmax of 1 hour, and the extended-release label a plasma peak around Week 6 to Week 7.6,2
What is the bioavailability of exenatide?
Is exenatide banned by WADA?
The 2026 WADA Prohibited List text read contains no occurrence of the word "exenatide".10 That search does not rule out that a category on the list covers it, and a list entry may use a class name instead.
Is exenatide FDA approved?
What did the EXSCEL trial find?
EXSCEL found that once-weekly extended-release exenatide was noninferior to placebo for cardiovascular safety but not superior for efficacy (hazard ratio 0.91; 95% CI 0.83 to 1.00; P = 0.06).3 All-cause death was 6.9% on exenatide and 7.9% on placebo (hazard ratio 0.86; 95% CI 0.77 to 0.97), which was not considered statistically significant on the basis of the hierarchical testing plan, and the authors call the rate of premature discontinuation of the trial regimen a major limitation.3 It enrolled 14,752 adults with type 2 diabetes, and Amylin Pharmaceuticals funded it.3
Did exenatide slow Parkinson's disease in trials?
The 96-week UK phase 3 trial of 194 people found no evidence to support exenatide as a disease-modifying treatment.5 The earlier 62-person trial reported an adjusted off-medication motor score difference of -3.5 points (p=0.0318) at 60 weeks, on-medication scores on MDS-UPDRS parts 1 to 4 did not differ significantly between groups, and its authors call the mechanism uncertain.4 The Lancet later published an expression of concern about the UK phase 3 trial report, and the PubMed record for that notice gives no reason.9
What are the common side effects of exenatide?
The Byetta label lists nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation and asthenia as the most common reactions.1 The Bydureon BCise label lists injection site nodule and nausea as reactions in 5% or more of patients, and carries a boxed warning on thyroid C-cell tumors seen in rats.2
What is the difference between Byetta and Bydureon?
Guides, tools and comparisons
References
- AstraZeneca Pharmaceuticals LP. Byetta (exenatide) injection, for subcutaneous use. US prescribing information, DailyMed version 26, 2025. Byetta label
- Bydureon BCise (exenatide extended-release) injectable suspension, for subcutaneous use. US prescribing information, FDA label supplement 209210s025, 2025. Bydureon BCise label
- Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017. PMID 28910237
- Athauda D, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017. PMID 28781108
- Vijiaratnam N, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3 randomised placebo-controlled trial. Lancet 2025. PMID 39919773
- Zhao X, et al. Exenatide pharmacokinetics in healthy Chinese subjects. Int J Clin Pharmacol Ther 2008. PMID 18793576
- Linnebjerg H, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007. PMID 17425627
- ClinicalTrials.gov. NCT01144338: Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). Registry entry, results posted 2018. NCT01144338
- The Editors of the Lancet. Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK. Lancet 2026. PMID 42330995
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list